AVEVA™ PI System™ will make a drug against Alzheimer's available to everyone
Biogen Inc. is an American multinational biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery, development and delivery of therapies for the treatment of neurological diseases to patients around the world.
For fiscal 2017, the company reported earnings of $2.539 billion, with annual revenue of $12.274 billion, an increase of 7.2% from the previous fiscal cycle. Biogen stock trades at more than $289 per share, and its market capitalization was valued at more than $63 billion as of November 2018. The company was ranked No. 245 on the 2018 Fortune 500 list of the largest companies in the United States. United by income.
Goals
- Provide Aducanumab affordably to one million patients.
- Reduce costs from $10,000 to $100-150 per gram.
- Predict batch quality to make changes in real time.
Challenges
- The ambitious goal of cost reduction required new production processes.
- Lack of visibility to correct problems in real time.
- They must meet strict regulatory requirements.
Solutions
- AVEVA™ PI System.
Results
- Real-time exception review
- Ability to adjust manufacturing processes in real time
- Reduced manufacturing costs and increased performance
“Our goal with the AVEVA PI System is to make it a central point of information that powers some of our really key, data-rich applications and work processes.”
Tim Alosi, Head of Global Data Analytics Team, Biogen